Results 21 to 30 of about 2,302,594 (308)

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. [PDF]

, 2012
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that the tumour micro-environment confers innate resistance to therapy. Here we
Barzily-Rokni, Michal, Chapman, Paul B, Cooper, Zachary A, Davis, Ashli, Du, Jinyan, Flaherty, Keith T, Frederick, Dennie T, Golub, Todd R, Gould, Joshua, Lo, Roger S, Mongare, Margaret M, Morikawa, Teppei, Ogino, Shuji, Qian, Zhi Rong, Ribas, Antoni, Shee, Kevin, Solit, David B, Straussman, Ravid, Wargo, Jennifer A   +18 more
core   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitro [PDF]

, 2017
Multi-drug strategies have been attempted to prolong the efficacy of existing antibiotics, but with limited success. Here we show that the evolution of multi-drug-resistant Escherichia coli can be manipulated in vitro by administering pairs of ...
Cronin, Leroy, Furusawa, Chikara, Galiñanes Reyes, Sabrina Galiñanes, Horinouchi, Takaaki, Tsuda, Soichiro, Yoshida, Mari   +5 more
core   +1 more source

Drug resistance and combating drug resistance in cancer

Cancer Drug Resistance, 2019
Cancer is the second leading cause of death in the US. Current major treatments for cancer management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy, endocrine therapy and immunotherapy. Despite the endeavors and achievements made in treating cancers during the past decades, resistance to classical chemotherapeutic agents ...
Wang, Xuan, Zhang, Haiyun, Chen, Xiaozhuo   +2 more
openaire   +3 more sources

Multiplex CRISPRi System Enables the Study of Stage-Specific Biofilm Genetic Requirements in Enterococcus faecalis

mBio, 2020
Enterococcus faecalis is an opportunistic pathogen, which can cause multidrug-resistant life-threatening infections. Gaining a complete understanding of enterococcal pathogenesis is a crucial step in identifying a strategy to effectively treat ...
Irina Afonina, June Ong, Jerome Chua, Timothy Lu, Kimberly A. Kline   +4 more
doaj   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

, 2014
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L., Goltsov, Alexey, Goltsov, Gregory, Harrison, David J., Langdon, Simon P.   +4 more
core   +5 more sources

Drug resistant tuberculosis [PDF]

BMJ, 1995
EDITOR,—Concern is growing over the spread of drug resistant Mycobacterium tuberculosis. New evidence suggests that this spread may be increasing in certain sections of the British population. The recent advances in molecular techniques have equipped us with the means to make substantial inroads into the possible impact of drug resistant tuberculosis.1
openaire   +4 more sources

The Value of Neutrophil Gelatinase-Associated Lipocalin Receptor as a Novel Partner of CD38 in Chronic Lymphocytic Leukemia: From an Adverse Prognostic Factor to a Potential Pharmacological Target?

Biomedicines, 2023
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B lymphocytes that escape death, and correlates with the expression of negative prognostic markers such as the CD38 antigen.
Brigitte Bauvois, Elise Chapiro, Claire Quiney, Karim Maloum, Santos A. Susin, Florence Nguyen-Khac   +5 more
doaj   +1 more source

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. [PDF]

, 2017
Acquired drug resistance prevents cancer therapies from achieving stable and complete responses. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells.
Berens, Michael E, Bole, Dhruv, Dhruv, Harshil D, Eaton, John K, Galeas, Jacqueline, Hangauer, Matthew J, Matov, Alexandre, McCormick, Frank, McManus, Michael T, Ryan, Matthew J, Schreiber, Stuart L, Viswanathan, Vasanthi S   +11 more
core   +1 more source

Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis

Microbiology Spectrum, 2023
Clofazimine (CFZ) has been repurposed for treating tuberculosis (TB), especially multidrug-resistant tuberculosis (MDR-TB). However, the mechanisms of resistance to clofazimine are poorly understood.
Lei Zhang, Ye Zhang, Yuanyuan Li, Fengmin Huo, Xi Chen, Hui Zhu, Shaochen Guo, Lei Fu, Bin Wang, Yu Lu   +9 more
doaj   +1 more source